# Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis

> **NCT04225312** · PHASE4 · UNKNOWN · sponsor: **Amsterdam UMC, location VUmc** · enrollment: 300 (estimated)

## Conditions studied

- Relapsing Remitting Multiple Sclerosis

## Interventions

- **DRUG:** Personalized extended interval dosing of natalizumab
- **DRUG:** Standard interval dosing

## Key facts

- **NCT ID:** NCT04225312
- **Lead sponsor:** Amsterdam UMC, location VUmc
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-02-03
- **Primary completion:** 2025-03-01
- **Final completion:** 2025-03-01
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2023-04-27

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04225312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04225312, "Personalized Extended Interval Dosing of Natalizumab in Relapsing Remitting Multiple Sclerosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04225312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*